analysts and calls -- Morgan Stanley Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- Morgan Stanley

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	9/30/2002 10:52:14 AM
From: tuck	Read Replies (2) of 31

>>Who are the current biotech analysts at Morgan Stanley<< >>CHICAGO, Sept 30 (Reuters) - Morgan Stanley on Monday cut its 12-month price target on Vertex Pharmaceuticals Inc. (NasdaqNM:VRTX - News) to $34 from $40, but maintained its "overweight" rating on the biotechnology firm. Morgan Stanley analysts Ian Somaiya and Caroline Copithorne, in a research note, said they raised revenue forecasts for AIDS drug VX-175, also known as 908, based on strong late-stage clinical data. The also said they expect Cambridge, Massachusetts-based Vertex and partner Aventis (Paris:AVEP.PA - News) to start a broader clinical program for experimental rheumatoid arthritis drug pralnacasan. "We believe this should support a more robust launch, but the size of the program should push approval and launch to 2006," they said in a research note.<< And just for fun, I see MS has started Weight Watchers with . . . Overweight! Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next